Aprea Therapeutics Inc (OQ:APRE)

Business Focus: Biotechnology & Medical Research

Apr 10, 2024 12:00 pm ET
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today released details about four poster presentations at the ongoing...
Mar 26, 2024 07:45 am ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended...
Mar 11, 2024 08:30 am ET
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with...
Mar 11, 2024 08:29 am ET
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Mar 05, 2024 04:45 pm ET
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of...
Feb 06, 2024 08:01 am ET
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND)...
Jan 30, 2024 08:00 am ET
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will deliver a...
Jan 04, 2024 04:05 pm ET
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans...
Nov 09, 2023 04:05 pm ET
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended...
Oct 24, 2023 08:00 am ET
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at...
Oct 16, 2023 08:30 am ET
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfo
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters presented at the AACR-NCI-EORTC...
Sep 19, 2023 08:00 am ET
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC...
Sep 11, 2023 08:00 am ET
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced updated preclinical data supporting development of the...
Sep 06, 2023 04:05 pm ET
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer,...
Aug 24, 2023 07:30 am ET
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierre Bizzari to its Board of...
Aug 10, 2023 07:30 am ET
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30,...
Jun 14, 2023 08:00 am ET
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren...
May 30, 2023 08:30 am ET
Aprea Therapeutics to Present at BIO International Convention
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren...
May 15, 2023 04:05 pm ET
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported...
May 08, 2023 08:00 am ET
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced...
Mar 30, 2023 04:05 pm ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported...
Mar 16, 2023 08:00 am ET
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an...
Mar 07, 2023 08:00 am ET
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren...
Mar 01, 2023 04:05 pm ET
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it...
Feb 27, 2023 04:05 pm ET
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the closing of...
Feb 22, 2023 08:41 pm ET
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the pricing of...
Feb 22, 2023 04:05 pm ET
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced it has...
Feb 15, 2023 08:00 am ET
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received an award notification from...
Feb 13, 2023 07:00 am ET
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced a one-for-twenty reverse...
Jan 30, 2023 08:00 am ET
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief...
Jan 19, 2023 08:00 am ET
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6th Annual...
Jan 11, 2023 08:00 am ET
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first patient was dosed in its...
Nov 09, 2022 04:15 pm ET
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the...
Sep 22, 2022 06:00 pm ET
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the abstract titled “ATRN-W1051, a...
Sep 08, 2022 08:00 am ET
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad Ph.D, President and Chief...
Aug 11, 2022 04:15 pm ET
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the...
Aug 02, 2022 08:00 am ET
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive...
May 16, 2022 09:21 am ET
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc....
Mar 15, 2022 04:15 pm ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months...
Jan 06, 2022 08:00 am ET
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman...
Dec 14, 2021 08:00 am ET
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hemat
Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of Aprea Therapeutics,...
Dec 13, 2021 08:00 am ET
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematol
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced updated results from its Phase 2 trial...
Dec 09, 2021 08:31 am ET
Thinking about buying stock in Aprea Therapeutics, Ocugen, JFrog, RedHill Biopharma, or New Oriental Education & Tech?
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, OCGN, FROG, RDHL, and EDU.
Dec 09, 2021 08:00 am ET
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug...
Nov 08, 2021 04:15 pm ET
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and...
Nov 04, 2021 04:15 pm ET
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that investigators will present data from...
Sep 20, 2021 04:15 pm ET
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Society of...
Sep 20, 2021 08:30 am ET
Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeutics, Spectrum Pharmaceuticals, or SmileDirectClub?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSTM, CRVS, APRE, SPPI, and SDC.
Sep 14, 2021 08:00 am ET
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for...
Aug 18, 2021 09:31 am ET
Thinking about buying stock in Aprea Therapeutics, Commscope, RealReal, Oramed Pharmaceuticals, or Verb Technology?
NEW YORK, Aug. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, COMM, REAL, ORMP, and VERB.
Aug 12, 2021 04:15 pm ET
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and...
Aug 12, 2021 06:00 am ET
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug...
Aug 05, 2021 05:00 pm ET
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug...
Jul 21, 2021 09:31 am ET
Thinking about buying stock in Chembio Diagnostics, Endo, Aprea Therapeutics, RealReal, or Amplify Energy?
NEW YORK, July 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, ENDP, APRE, REAL, and AMPY.
Jul 21, 2021 08:00 am ET
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced positive results from its Phase 2 trial...
Jun 16, 2021 09:31 am ET
Thinking about buying stock in Aprea Therapeutics, RA Medical Systems, AMC Entertainment, Torchlight Energy Resources, or Appharvest?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, RMED, AMC, TRCH, and APPH.
Jun 16, 2021 08:00 am ET
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Phase 1/2 trial evaluating the...
May 21, 2021 06:00 am ET
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President...
May 18, 2021 06:00 am ET
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and...
May 06, 2021 04:15 pm ET
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months...
Apr 16, 2021 09:15 am ET
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day...
Apr 08, 2021 11:15 am ET
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug...
Mar 16, 2021 04:15 pm ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months...
Jan 08, 2021 08:00 am ET
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman...
Dec 28, 2020 08:00 am ET
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from...
Nov 30, 2020 08:00 am ET
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug...
Nov 19, 2020 08:00 am ET
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman...
Nov 05, 2020 04:15 pm ET
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and...
Oct 30, 2020 04:00 am ET
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with...
Oct 14, 2020 08:00 am ET
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com. The new...
Oct 07, 2020 08:00 am ET
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food and Drug...
Sep 29, 2020 08:00 am ET
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A....
Sep 18, 2020 08:00 am ET
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S....
Sep 03, 2020 08:00 am ET
Aprea Therapeutics to Present at Upcoming Investor Conferences
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that  the Company is scheduled to present...
Aug 11, 2020 04:15 pm ET
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and six...
Jul 16, 2020 07:00 am ET
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the expansion of patient enrollment in...
Jun 29, 2020 07:00 am ET
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointments of Fouad...
Jun 12, 2020 06:00 am ET
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia a
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the oral presentation of updated data...
Jun 03, 2020 08:00 am ET
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that patient enrollment in its Phase 3...
May 18, 2020 08:00 am ET
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President and...
May 15, 2020 07:30 am ET
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three months...
Apr 27, 2020 07:00 am ET
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Aprea Therapeutics, Inc. (NASDAQ: APRE). If you are a shareholder of Aprea Therapeutics, Inc. and wish to receive...
Apr 06, 2020 08:00 am ET
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned...
Mar 26, 2020 08:00 am ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three months and...
Feb 13, 2020 08:00 am ET
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Gregory S....
Jan 30, 2020 07:30 am ET
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that the U.S. Food and Drug Administration...
Jan 09, 2020 08:00 am ET
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that Christian S. Schade, President &...
Dec 12, 2019 08:30 am ET
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presen
Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting. Both trials are evaluating the safety and...
Dec 09, 2019 11:00 am ET
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented preliminary results at the 2019 ASH Annual...
Dec 09, 2019 11:00 am ET
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented results at the 2019 ASH Annual Meeting from its...
Nov 14, 2019 04:15 pm ET
Aprea Therapeutics Reports Third Quarter 2019 Financial Results
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and nine...
Nov 06, 2019 09:15 am ET
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that it will present updated data from two...
Oct 07, 2019 04:15 pm ET
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the closing of its initial public...
Oct 02, 2019 11:03 pm ET
Aprea Therapeutics Announces Pricing of Initial Public Offering
Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of 5,666,667...
May 12, 2016 05:38 pm ET
Aperture Health, Inc's., Subsidiary CSS Alliance LLC announces Joint Venture and Worldwide Exclusive Distribution agreement with Korean product development and manufacturing entity
NEW YORK, May 12, 2016 /PRNewswire/ - Aperture Health, Inc. (OTC Markets.com: APRE) and CSS Alliance LLC ("CSS"), are pleased to announce that the company has branched out and signed a Joint Venture agreement which includes an exclusive worldwide distribution agreement with CSS Korea R&D Co., Ltd for new technologies and products that include solar powered A/C units, and powerless generators, as well as solar powered boilers.  
Apr 20, 2016 09:00 am ET
Aperture Health, Inc.'s., Subsidiary CSS Alliance LLC Begins Process to Distribute Solar Power A/C Units and Generators through New Vertical Business Relationships in Korea
NEW YORK, April 20, 2016 /PRNewswire/ - Aperture Health, Inc. (OTC Markets.com: APRE), is pleased to announce that the company's wholly owned subsidiary CSS Alliance has formed a worldwide exclusive distribution agreement with House Tech. Co. Ltd to become a hub in the United States to distribute, market and sell new technologies ranging from green solar powered A/C units, and powerless generators, as well as solar energy.  
Mar 08, 2016 08:30 am ET
CSS Alliance LLC Launches New Web Site and is in Negotiation to Acquire Container Company
NEW YORK, March 8, 2016 /PRNewswire/ - CSS Alliance (OTCMarkets.com: APRE) is pleased to announce that the company has launched its new web site www.css-alliance.com. The website will help to accommodate our new clients, customers and our shareholders. The company also announced that it is in negotiation to acquire another horizontal acquisition of a container company in the same business space as CSS Alliance. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.